Antiangiogenic therapies for non-small-cell lung cancer

Suresh S. Ramalingam, Chandra P. Belani

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.

Original languageEnglish (US)
Title of host publicationAdvances in Personalized Therapy for Lung Cancer
PublisherFuture Medicine Ltd.
Pages39-51
Number of pages13
ISBN (Electronic)9781780840345
ISBN (Print)9781780841175
DOIs
StatePublished - Nov 1 2011

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antiangiogenic therapies for non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Ramalingam, S. S., & Belani, C. P. (2011). Antiangiogenic therapies for non-small-cell lung cancer. In Advances in Personalized Therapy for Lung Cancer (pp. 39-51). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.217